As part of the stock split, every share with a face value of Rs 10 each will be split into five equity shares with a face value of Rs 5 each. As part of the bonus issue, eligible shareholders will receive one bonus share for every share they own as on the record date.
While bonus issue and stock split increases the total number of outstanding shares, it does not change the company’s market capitalisation. However, they can improve liquidity and affordability, allowing more investors to add shares of the company to their portfolio.Anlon Healthcare has set April 24 (Friday) as the record date for the bonus issue and stock split. This means that only those shareholders who own the shares of the company in their demat accounts will be eligible for the two corporate actions. Given the T+1 settlement norm, today marks the last day investors can buy the shares of the company so that the shares are credited to their accounts by tomorrow and they become eligible for the bonus issue and stock split.
Anlon Healthcare shares made a muted market debut in September last year, listing at Rs 92 apiece on NSE. This marked a 1% premium over the IPO price of Rs 91 per share. This came even as the Rs 121-crore IPO of the pharmaceutical intermediates and active pharmaceutical ingredients (APIs)-maker saw strong investor interest during its three days of public bidding, being subscribed over 7 times its offer size.
Anlon Healthcare shares strongly surged after the debut, rallying nearly 88% in a little over two months to hit an all-time high of Rs 172.75 apiece in November 2025. The stock however declined around 14% to Thursday’s intraday high of Rs 149.4 per share. The stock is still over 62% higher than its listing price.